Pharma Journalist -

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, announced that the first patient has been…
Read More...

Pfizer Inc. announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy…
Read More...

Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of…
Read More...

GSK Singapore announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab), which may now be used in combination with…
Read More...

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three…
Read More...

Servier announced that the U.S. Food and Drug Administration (FDA) has approved VORANIGO, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated…
Read More...

Sangamo Therapeutics, Inc., a genomic medicine company, announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously…
Read More...

SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving both the small molecule and cell & gene therapy industry, and Rznomics Inc.,…
Read More...

Roche announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO,…
Read More...

Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now…
Read More...